Zum Inhalt

HealthOSArzneimittel

Arbeitsbereiche

Nachschlagen

Wirkstoffe & Arzneimittelsicherheit

Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-26 · 1181 Präparate · 62955 Quellenpassagen · 167 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Quellenpassagen (1)

Nebenwirkungen · Columvi

Columvi 2.5 mg concentrate for solution for infusion Columvi 10 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 19

HOS-149211 · Präparat HOS-100012

General disorders and administration Pyrexia Very common Uncommon site conditions Aspartate aminotransferase increased Very common Common Alanine aminotransferase increased Very common Common Blood alkaline phosphatase increased Very common Uncommon Gamma-glutamyltransferase increased Very common Common Investigations Blood lactate dehydrogenase Very common Very rare** increased Blood bilirubin increased18 Common Very rare** Hepatic enzyme increased Uncommon Very rare** * Grade 5 reactions reported. See Description of selected adverse reactions. ** No Grade 3-4 events were reported. 1 Includes COVID-19, COVID-19 pneumonia, and SARS-CoV-2 test positive. 2 Includes upper respiratory tract infection, lower respiratory tract infection, respiratory tract infection, and respiratory tract infection bacterial. 3 Includes pneumonia, pneumonia bacterial, and pneumonia pneumococcal. 4 New onset or reactivation. Includes cytomegalovirus infection, cytomegalovirus test positive, cytomegalovirus infection reactivation and cytomegalovirus viraemia. 5 New onset or reactivation. Includes herpes zoster and herpes virus infection. 6 Includes urinary tract infection and urosepsis. 7 Includes sepsis, streptococcal sepsis, septic shock, and enterococcal sepsis. 8 Includes oral candidiasis and candida infection. 9 Includes tumour flare and tumour pain. 10 Based on ASTCT consensus grading (Lee 2019). 11 Includes neuropathy peripheral, peripheral sensory neuropathy, dysaesthesia, paraesthesia, hypoaesthesia, peripheral motor neuropathy, and polyneuropathy. 12 Includes confusional state, delirium, and ICANS. 13 Includes abdominal pain, abdominal discomfort, abdominal pain upper, abdominal pain lower, and gastrointestinal pain. 14 Includes colitis, colitis ischaemic, and enterocolitis. 15 Includes pancreatitis and pancreatitis acute. 16 Includes rash, rash pruritic, rash maculo-papular, erythema, pruritus, rash erythematous, urticaria, and erythema multiforme. 17 Includes arthralgia, musculoskeletal pain, back pain, bone pain, myalgia, neck pain, pain in extremity, musculoskeletal chest pain, and non-cardiac chest pain. 18 Includes blood bilirubin increased and hyperbilirubinaemia.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-10-20T13:00:00Z · SHA-256 2c5f4e2a70d7830059221b97eb832e6bb8ef846ec2df0243e5154b9f1ae1a38f · Passage e9149a1139466abb8c27e5b1dcff72746de9124589742bb166c6ff179f6b73f8 · Zeichen 13044–15863 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.